<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02525055</url>
  </required_header>
  <id_info>
    <org_study_id>RVL-vCS-003</org_study_id>
    <nct_id>NCT02525055</nct_id>
  </id_info>
  <brief_title>Characterisation of a New Wild-Type H3N2 Virus for the Human Viral Challenge Model</brief_title>
  <official_title>A Randomised, Double Blind Study To Characterise Influenza A/Perth/16/2009(H3N2) Virus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hvivo</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hvivo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will characterise Influenza A/Perth/16/2009(H3N2) virus in healthy participants
      using the viral challenge model. The study includes two cohorts.

      Cohort 1: A randomised, double-blind study of 4 titres of Challenge Virus to determine the
      optimum titre.

      Cohort 2: An open-label extension arm in which all participants will receive the 'optimum'
      titre as identified from Cohort 1.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Influenza and its associated diseases are a major cause of morbidity and mortality. The
      United States Advisory Committee on Immunization Practices recommends influenza vaccination
      for everyone over 6 months of age. The failure of the flu vaccine in 2014-2015 demonstrates
      the need for a model that allows the rapid development of novel antivirals,
      universal/intra-seasonal vaccines, immunomodulators, monoclonal antibodies and other novel
      treatments. Studies using experimental influenza virus infection in human participants have
      demonstrated that adult volunteers can be infected by nasal inoculation, and experimental
      infection is safe and not associated with transmission to contacts. The experimental virus is
      manufactured in compliance with Good Manufacturing Practice for use in the Human Viral
      Challenge Model.

      The investigators chose an H3N2 influenza subtype given that this strain has the most
      substantial impact in terms of morbidity or mortality annually as described by the Centre for
      Disease Control . The investigators first subjected the virus batch to rigorous adventitious
      agent testing, then confirmed the virus to be wild-type by Sanger sequencing and finally
      determined the virus titres appropriate for human use via the established ferret model. hVIVO
      team built on its previous experience with other H3N2 and H1N1 viruses to develop this unique
      model.

      The first part of study (Cohort 1) was to determine the safety and optimal virus titre in
      healthy adult volunteers using our unique clinical quarantine facility in London, UK. After
      the first part of the study was completed, the study was amended to add an older population
      group (45-64 years old) in order to characterise the course of infection in an age group
      better representing the at-risk population.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">August 11, 2014</completion_date>
  <primary_completion_date type="Actual">August 11, 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Cohort 1 (including 4 arms) is double blinded. Cohort 2 (including 1 arm divided in 2 separate age comparison groups) is open labelled. In order to allow for an age comparison between subjects aged 18 to 45 and subjects aged 56 to 64, data from Cohort 2 (Infectious Titre 5) will be presented in 2 separate reporting groups.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Curve of Virus Load</measure>
    <time_frame>8 days</time_frame>
    <description>Area under the curve (AUC) of the Challenge Viral load, measured by nasopharyngeal swab quantitative polymerase chain reaction [qPCR], from Day 1 to Day 8 post-Viral Challenge. Nasopharyngeal swabs are collected up to 3 times per day ( every 8 hours +/- 30mins)</description>
  </primary_outcome>
  <other_outcome>
    <measure>Incidence (Number and Percentage [%]) of Viral Challenge Emergent Adverse Events</measure>
    <time_frame>8 days</time_frame>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Infectious titre 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 participants aged 18 to 45 were inoculated with 1mL containing 2.8 x 10*3 TCID50 of virus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infectious titre 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 participants aged 18 to 45 were inoculated with 1mL containing 2.5 x 10*4 TCID50 of virus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infectious titre 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 participants aged 18 to 45 were inoculated with 1mL containing 3.6 x 10*5 TCID50 of virus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infectious titre 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 participants aged 18 to 45 were inoculated with 1mL containing 4.7 x 10*6 TCID50 of virus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infectious titre 5 (age 18 to 45 y)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 participants aged 18 to 45 were inoculated with 1mL containing 3.5 x 10*5 TCID50 of virus.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infectious titre 5 (age 46 to 64 y)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>16 participants aged 46 to 64 were inoculated with 1mL containing 3.5 x 10*5 TCID50 of virus.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Infectious titre 1 (H3N2)</intervention_name>
    <description>Infectious titre 1: 2.8 x 10*3 TCID50/mL</description>
    <arm_group_label>Infectious titre 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Infectious titre 2 (H3N2)</intervention_name>
    <description>Infectious titre 2: 2.5 x 10*4 TCID50/mL</description>
    <arm_group_label>Infectious titre 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Infectious titre 3 (H3N2)</intervention_name>
    <description>Infectious titre 3: 3.6 x 10*5 TCID50/mL</description>
    <arm_group_label>Infectious titre 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Infectious titre 4 (H3N2)</intervention_name>
    <description>Infectious titre 4: 4.7 x 10*6 TCID50/mL</description>
    <arm_group_label>Infectious titre 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Infectious titre 5 (H3N2) (Subjects aged 18 to 45 years old)</intervention_name>
    <description>Infectious titre 5: 3.5 x 10*5 TCID50/mL</description>
    <arm_group_label>Infectious titre 5 (age 18 to 45 y)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Infectious titre 5 (H3N2) (Subjects aged 46 to 64 years old)</intervention_name>
    <description>Infectious titre 5: 3.5 x 10*5 TCID50/mL</description>
    <arm_group_label>Infectious titre 5 (age 46 to 64 y)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  In good health with no history of major medical conditions.

          -  A total body weight ≥ 50 kg and a BMI of &gt;18.

          -  Acceptable forms of effective contraception.

          -  An informed consent document signed and dated by the subject and Investigator.

          -  Sero-suitable for Challenge Virus.

        Exclusion Criteria:

          -  Subjects who have a significant history of any tobacco use at any time (≥ total 10
             pack year history, e.g. one pack a day for 10 years).

          -  Subjects who have been pregnant within six months prior to the study, or who have a
             positive pregnancy test at any point in the study.

          -  Any history or evidence of any clinically significant medical conditions
             (cardiovascular, gastrointestinal, endocrinological, haematological, hepatic,
             immunological, metabolic, urological, neurological, psychotic, renal, and/or other
             major disease or malignancy).

          -  History or evidence of autoimmune disease or known immunodeficiency of any cause.

          -  Subjects with any history of asthma, COPD, pulmonary hypertension, reactive airway
             disease, or chronic lung condition of any aetiology.

          -  Positive human immunodeficiency virus (HIV), Hepatitis A (HAV), B (HBV), or C (HCV)
             test.

          -  Any significant abnormality altering the anatomy of the nose or nasopharynx.

          -  Any clinically significant history of epistaxis (nose bleeds).

          -  Any nasal or sinus surgery within six months of inoculation.

          -  Recurrent history of clinically significant autonomic dysfunction.

          -  Any abnormal laboratory test or ECG.

          -  Confirmed positive test for drugs of abuse.

          -  Venous access deemed inadequate for the phlebotomy and cannulation.

          -  Any known allergies to the excipients in the Challenge Virus inoculums.

          -  Health care workers who work in units with severely immuno-compromised patients.

          -  Evidence of vaccinations within the four weeks prior to Human Viral Challenge or
             intention to receive travel vaccination before the last study visit.

          -  Receipt of blood or blood products, or loss (including blood donations) of 450 mL or
             more of blood, during the 3 months prior to inoculations.

          -  Presence of significant respiratory symptoms existing on the day of challenge or
             between admission to the unit and inoculation with virus.

          -  History suggestive of respiratory infection within 14 days prior to admission to the
             unit.

          -  Use within 28 days prior to Human Viral Challenge (Day 0) of nasal steroids * Use
             within seven days of any other medication or product (prescription or
             over-the-counter), for symptoms of hay fever, rhinitis, nasal congestion or
             respiratory tract infection.

          -  Receipt of systemic: glucocorticoids, antiviral drugs, or immunoglobulins (Igs) or any
             other cytotoxic or immunosuppressive drug.

          -  Receipt of any systemic chemotherapy agent at any time.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bryan Muray, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hvivo</affiliation>
  </overall_official>
  <results_reference>
    <citation>Fullen DJ, Noulin N, Catchpole A, Fathi H, Murray EJ, Mann A, Eze K, Balaratnam G, Borley DW, Gilbert A, Lambkin-Williams R. Correction: Accelerating Influenza Research: Vaccines, Antivirals, Immunomodulators and Monoclonal Antibodies. The Manufacture of a New Wild-Type H3N2 Virus for the Human Viral Challenge Model. PLoS One. 2016 Jun 9;11(6):e0157211. doi: 10.1371/journal.pone.0157211. eCollection 2016.</citation>
    <PMID>27280602</PMID>
  </results_reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>August 6, 2015</study_first_submitted>
  <study_first_submitted_qc>August 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2015</study_first_posted>
  <results_first_submitted>November 7, 2019</results_first_submitted>
  <results_first_submitted_qc>January 23, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 27, 2020</results_first_posted>
  <last_update_submitted>January 23, 2020</last_update_submitted>
  <last_update_submitted_qc>January 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Flu</keyword>
  <keyword>Influenza</keyword>
  <keyword>Human Viral Challenge Model</keyword>
  <keyword>Wild-Type</keyword>
  <keyword>H3N2</keyword>
  <keyword>Universal Influenza Vaccine</keyword>
  <keyword>Intra-seasonal vaccines</keyword>
  <keyword>Antiviral</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Infectious Titre 1</title>
          <description>Infectious titre 1:
6 subjects aged 18 to 45 received 1mL containing 2.8 x 10*3 TCID50
Infectious titre 1: 2.8 x 10*3 TCID50/mL</description>
        </group>
        <group group_id="P2">
          <title>Infectious Titre 2</title>
          <description>Infectious titre 2:
6 subjects aged 18 to 45 received 1mL containing 2.5 x 10*4 TCID50
Infectious titre 2: 2.5 x 10*4 TCID50/mL</description>
        </group>
        <group group_id="P3">
          <title>Infectious Titre 3</title>
          <description>Infectious titre 3:
6 subjects aged 18 to 45 received 1mL containing 3.6 x 10*5 TCID50
Infectious titre 3: 3.6 x 10*5 TCID50/mL</description>
        </group>
        <group group_id="P4">
          <title>Infectious Titre 4</title>
          <description>Infectious titre 4:
6 subjects aged 18 to 45 received 1mL containing 4.7 x 10*6 TCID50
Infectious titre 4: 4.7 x 10*6 TCID50/mL</description>
        </group>
        <group group_id="P5">
          <title>Infectious Titre 5 (18 to 45 Years Old)</title>
          <description>Infectious titre 5:
6 subjects aged 18 to 45 received 1mL containing 3.5 x 10*5 TCID50
Infectious titre 5: 3.5 x 10*5 TCID50/mL</description>
        </group>
        <group group_id="P6">
          <title>Infectious Titre 5 (46 to 64 Years Old)</title>
          <description>Infectious titre 5:
16 subjects aged 46 to 64 received 1mL containing 3.5 x 10*5 TCID50
Infectious titre 5: 3.5 x 10*5 TCID50/mL</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Infectious Titre 1</title>
          <description>6 participants aged 18 to 45 inoculated with 1mL containing 2.8 x 10*3 TCID50</description>
        </group>
        <group group_id="B2">
          <title>Infectious Titre 2</title>
          <description>6 participants aged 18 to 45 inoculated with 1mL containing 2.5 x 10*4 TCID50</description>
        </group>
        <group group_id="B3">
          <title>Infectious Titre 3</title>
          <description>6 participants aged 18 to 45 inoculated with 1mL containing 3.6 x 10*5 TCID50</description>
        </group>
        <group group_id="B4">
          <title>Infectious Titre 4</title>
          <description>6 participants aged 18 to 45 inoculated with 1mL containing 4.7 x 10*6 TCID50</description>
        </group>
        <group group_id="B5">
          <title>Infectious Titre 5 (18 to 45 Years Old)</title>
          <description>6 participants aged 18 to 45 inoculated with 1mL containing 3.5 x 10*5 TCID50</description>
        </group>
        <group group_id="B6">
          <title>Infectious Titre 5 (46 to 64 Years Old)</title>
          <description>16 participants aged 46 to 64 inoculated with 1mL containing 3.5 x 10*5 TCID50</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="16"/>
            <count group_id="B7" value="46"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="16"/>
                    <measurement group_id="B7" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="11"/>
                    <measurement group_id="B7" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="16"/>
                    <measurement group_id="B7" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve of Virus Load</title>
        <description>Area under the curve (AUC) of the Challenge Viral load, measured by nasopharyngeal swab quantitative polymerase chain reaction [qPCR], from Day 1 to Day 8 post-Viral Challenge. Nasopharyngeal swabs are collected up to 3 times per day ( every 8 hours +/- 30mins)</description>
        <time_frame>8 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Infectious Titre 1</title>
            <description>Participants aged 18 to 45 received 1mL containing 2.8 x 10*3 TCID50</description>
          </group>
          <group group_id="O2">
            <title>Infectious Titre 2</title>
            <description>Participants aged 18 to 45 received 1mL containing 2.5 x 10*4 TCID50</description>
          </group>
          <group group_id="O3">
            <title>Infectious Titre 3</title>
            <description>Participants aged 18 to 45 received 1mL containing 3.6 x 10*5 TCID50</description>
          </group>
          <group group_id="O4">
            <title>Infectious Titre 4</title>
            <description>Participants aged 18 to 45 received 1mL containing 4.7 x 10*6 TCID50</description>
          </group>
          <group group_id="O5">
            <title>Infectious Titre 5 (18 to 45 Years Old)</title>
            <description>Participants aged 18 to 45 received 1mL containing 3.5 x 10*5 TCID50</description>
          </group>
          <group group_id="O6">
            <title>Infectious Titre 5 (46 to 64 Years Old)</title>
            <description>Participants aged 46 to 64 received 1mL containing 3.5 x 10*5 TCID50</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve of Virus Load</title>
          <description>Area under the curve (AUC) of the Challenge Viral load, measured by nasopharyngeal swab quantitative polymerase chain reaction [qPCR], from Day 1 to Day 8 post-Viral Challenge. Nasopharyngeal swabs are collected up to 3 times per day ( every 8 hours +/- 30mins)</description>
          <units>mins*Eq log10 TCID50/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2081.98" spread="869.61"/>
                    <measurement group_id="O2" value="18,973.90" spread="1048.23"/>
                    <measurement group_id="O3" value="15,944.09" spread="13751.39"/>
                    <measurement group_id="O4" value="12,201.14" spread="8877.43"/>
                    <measurement group_id="O5" value="9563.26" spread="10,536.96"/>
                    <measurement group_id="O6" value="11,710.28" spread="11833.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Incidence (Number and Percentage [%]) of Viral Challenge Emergent Adverse Events</title>
        <time_frame>8 days</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events are collected throughout the study from screening to last study visit (108 days)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Infectious Titre 1</title>
          <description>Infectious titre 1:
6 participants aged 18 to 45 were inoculated with 1mL containing 2.8 x 10*3 TCID50
Infectious titre 1: 2.8 x 10*3 TCID50/mL</description>
        </group>
        <group group_id="E2">
          <title>Infectious Titre 2</title>
          <description>Infectious titre 2:
6 participants aged 18 to 45 were inoculated with 1mL containing 2.5 x 10*4 TCID50
Infectious titre 2: 2.5 x 10*4 TCID50/mL</description>
        </group>
        <group group_id="E3">
          <title>Infectious Titre 3</title>
          <description>Infectious titre 3:
6 participants aged 18 to 45 were inoculated with 1mL containing 3.6 x 10*5 TCID50
Infectious titre 3: 3.6 x 10*5 TCID50/mL</description>
        </group>
        <group group_id="E4">
          <title>Infectious Titre 4</title>
          <description>Infectious titre 4:
6 participants aged 18 to 45 were inoculated with 1mL containing 4.7 x 10*6 TCID50
Infectious titre 4: 4.7 x 10*6 TCID50/mL</description>
        </group>
        <group group_id="E5">
          <title>Infectious Titre 5 (Aged 18 to 45)</title>
          <description>6 participants aged 18 to 45 were inoculated with 1mL containing 3.5 x 10*5 TCID50
Infectious titre 5: 3.5 x 10*5 TCID50/mL</description>
        </group>
        <group group_id="E6">
          <title>Infectious Titre 5 (Aged 45 to 64)</title>
          <description>16 participants aged 46 to 64 were inoculated with 1mL containing 3.5 x 10*5 TCID50
Infectious titre 5: 3.5 x 10*5 TCID50/mL</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA v16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Rash pustular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Candida infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Spirometry abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>ALT increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>AST increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Reticulocyte count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Vital capacity decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Nasal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Nicolas Noulin</name_or_title>
      <organization>hVIVO Services Limeted</organization>
      <phone>+442077561365</phone>
      <email>n.noulin@hvivo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

